Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

Also called NCT07929350

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Beijing Supreme Life Pharmaceutical Technology Co., Ltd. (from the registry)
Registry
  • NCT NCT07929350
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07929350. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-20 (anticipated); primary completion 2028-01-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Fuling Yunhua Granules
Intervention (Drug)
Dihuang Baoyuan Granules
Intervention (Drug)
Fuling Yunhua Granules Matched Placebo
Intervention (Drug)
Dihuang Baoyuan Granules Matched Placebo
Intervention (Drug)
Metformin
Intervention (Drug)
Metformin Matched Placebo
Lead sponsor
Beijing Supreme Life Pharmaceutical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07929350
Content hash
b3082974aa1421877e454bdb68c1790d08b8178f97db83aecf151987d0380447